Abstract

Simple SummaryDespite advances in primary and adjuvant treatments, approximately 50% of colorectal cancer (CRC) patients still die from recurrence and metastatic disease. Thus, alternative and more effective therapeutic approaches are expected to be developed. Drug repurposing is increasing interest in cancer therapy, as it represents a cheaper and faster alternative strategy to de novo drug synthesis. Psychiatric medications are promising as a new generation of antitumor drugs. Here, we demonstrate that spiperone—a licensed drug for the treatment of schizophrenia—induces apoptosis in CRC cells. Our data reveal that spiperone’s cytotoxicity in CRC cells is mediated by phospholipase C activation, intracellular calcium homeostasis dysregulation, and irreversible endoplasmic reticulum stress induction, resulting in lipid metabolism alteration and Golgi apparatus damage. By identifying new targetable pathways in CRC cells, our findings represent a promising starting point for the design of novel therapeutic strategies for CRC.Approximately 50% of colorectal cancer (CRC) patients still die from recurrence and metastatic disease, highlighting the need for novel therapeutic strategies. Drug repurposing is attracting increasing attention because, compared to traditional de novo drug discovery processes, it may reduce drug development periods and costs. Epidemiological and preclinical evidence support the antitumor activity of antipsychotic drugs. Herein, we dissect the mechanism of action of the typical antipsychotic spiperone in CRC. Spiperone can reduce the clonogenic potential of stem-like CRC cells (CRC-SCs) and induce cell cycle arrest and apoptosis, in both differentiated and CRC-SCs, at clinically relevant concentrations whose toxicity is negligible for non-neoplastic cells. Analysis of intracellular Ca2+ kinetics upon spiperone treatment revealed a massive phospholipase C (PLC)-dependent endoplasmic reticulum (ER) Ca2+ release, resulting in ER Ca2+ homeostasis disruption. RNA sequencing revealed unfolded protein response (UPR) activation, ER stress, and induction of apoptosis, along with IRE1-dependent decay of mRNA (RIDD) activation. Lipidomic analysis showed a significant alteration of lipid profile and, in particular, of sphingolipids. Damage to the Golgi apparatus was also observed. Our data suggest that spiperone can represent an effective drug in the treatment of CRC, and that ER stress induction, along with lipid metabolism alteration, represents effective druggable pathways in CRC.

Highlights

  • According to the recent GLOBOCAN statistics, colorectal cancer (CRC) represents nearly 1 out of 10 cancer cases and deaths worldwide

  • We have recently reported the cytotoxic effects of the antipsychotic spiperone at clinically relevant concentrations (IC50 < 10 μmol/L) on MCF7 breast cancer and HCT116 and SW620 CRC cell lines [34]

  • We previously demonstrated that Ca2+ and phospholipase C (PLC) are involved in spiperone-induced cell death

Read more

Summary

Introduction

According to the recent GLOBOCAN statistics, colorectal cancer (CRC) represents nearly 1 out of 10 cancer cases and deaths worldwide. Despite the emergence of several screening programs to reduce the incidence of CRC, nearly a quarter of CRC cases are diagnosed at an advanced stage with metastases, and as many as 50% of patients who present with non-metastatic CRC develop metachronous metastases, resulting in difficulties in curative surgical control and subsequent tumor-related deaths— in elderly patients [2,3]. The 5-year relative survival rate for CRC is 90% for patients diagnosed with localized disease, but drops to 14% for those diagnosed with stage IV disease [9]. These figures indicate that further investigation is still required in order to develop alternative and effective approaches for medical intervention, especially in advanced stages and in the most vulnerable patients

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call